Novartis ianalumab two-year data at ACR show further improvements in Sjögren’s disease activity
Basel, November 10, 2026 – Novartis today presented long-term results from the ongoing NEPTUNUS extension study of ianalumab in Sjögren’s disease at the American College of Rheumatology Convergence 2026. The data showed that the reduction in systemic disease activity continued to deepen from Week 48 through Week 108 among patients who continued ianalumab 300 mg monthly as measured by EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). 1